Mallinckrodt stock was down 6.7% today on a whistleblower lawsuit that alleged the same thing that short sellers have been alleging for years - the company doesn't have any fucking clue what's in the one drug it has used to, at one point, make itself into a $10 billion plus company and the drug doesn't seem to have any robust double blind clinical data supporting its use in most of its nearly 17 off label uses. This could be the most appaling pharmaceutical story in history and its been unfolding under our noses - and without regulators doing a thing about it - for nearly a decade. 

All content created and owned by Quoth the Raven Research, LLC. 

QTR Podcasts are always free, but some people choose to make a small recurring donation, which is gratefully accepted: https://www.patreon.com/QTRResearch

All podcast content is subject to the following disclaimer: http://www.quoththeravenresearch.com/disclaimerterms-of-service/

Visit www.quoththeravenresearch.com for more on QTR.